Loading
CX-908 is an experimental masked T-cell engager from CytomX Therapeutics, in preclinical development for solid tumours.
CX-908 is a masked T-cell engager (Probody TCB) from CytomX Therapeutics. A masked bispecific T-cell engager against P-cadherin and CD3; the source gives no further detail. Its furthest stage is preclinical development, for solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.
A masked bispecific T-cell engager against P-cadherin and CD3; the source gives no further detail. Connects to CD3.
1.One arm of CX-908 binds CD3 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CX-908" OR ABSTRACT:"CX-908") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CX-908, not a curated reading list.
Shares CytomX Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CytomX Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CytomX Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CD3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CytomX Therapeutics and the tag pipeline.
Shares CD3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CD3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/